DCOY · Decoy Therapeutics Inc. · Insider Trading

Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.

Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock split effective on March 6, 2026.

Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.

Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months.

Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock split effective on March 6, 2026.

Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.

Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.

Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months.

Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.

Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.

Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months.

Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.

Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.

Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.

Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.

Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months.

Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.

Shares beneficially owned following the transaction is adjusted to reflect the reverse stock splits effective on June 16, 2024 and August 17, 2025.

Includes 20 shares of unvested restricted stock granted on January 3, 2023.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7437 to $0.75, inclusive. The reporting person undertakes to provide to Salarius Pharmaceuticals, Inc., any security holder of Salarius Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

25% of the options are vested on February 20, 2025, and 1/36 of the remaining options vest on each monthly anniversary thereafter for 36 months.

Restricted stock granted under the Salarius Pharmaceuticals, Inc. 2015 Equity Incentive Plan in lieu of cash for performance bonus. The shares of common stock are subject to a six-month holding period pursuant to the terms of the restricted stock agreement.

Restricted stock granted under the Salarius Pharmaceuticals, Inc. 2015 Equity Incentive Plan in lieu of cash for performance bonus. The shares of common stock are subject to a six-month holding period pursuant to the terms of the restricted stock agreement

Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 25% of the shares of restricted stock will vest on January 2, 2024, and 1/36 of the remaining shares of restricted stock will vest on monthly anniversary thereafter.

Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024

Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 25% of the shares of restricted stock will vest on January 2, 2024, and 1/36 of the remaining shares of restricted stock will vest on monthly anniversary thereafter.

Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024

Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024

Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024

Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024

Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024

The Reporting Person's previous Form 4 filed on November 7, 2022 and amended on November 8, 2022 incorrectly reported the Reporting Person acquiring 7,314 shares of common stock under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c), when it should have been reported as 1,488 shares of common stock.

The Reporting Person's previous Form 4 filed on November 7, 2022 and amended on November 8, 2022 incorrectly reported the Reporting Person acquiring 10,000 shares of common stock under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c), when it should have been reported as 2,693 shares of common stock.

The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuant to the issuer's Employee Stock Purchase Plan.

The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuant to the issuer's Employee Stock Purchase Plan.

The Registrant issued these shares to the reporting person as part of his bonus; which shares were issued in lieu of net cash compensation. The shares were issued at the fair market value of the Registrants common stock on the date of grant.

The Registrant issued these shares to the reporting person as part of his bonus; which shares were issued in lieu of net cash compensation. The shares were issued at the fair market value of the Registrants common stock on the date of grant.